Meta-analysis of FKBP5 gene polymorphisms association with treatment response in patients with mood disorders

Neuroscience Letters

Volumn 484, Issue 1, 2010, Pages 56-61

  Zou, Yan Feng ^a   Wang, Fang ^a   Feng, Xiao Liang ^a   Li, Wen Fei ^b   Tao, Jin Hui ^c   Pan, Fa Ming ^a   Huang, Fen ^a   Su, Hong ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b Department of Psychiatry   (China)

^c ANHUI PROVINCIAL HOSPITAL   (China)

Author keywords

FKBP5; Meta analysis; Mood disorders; Polymorphism; Treatment response

Indexed keywords

CITALOPRAM; FLUOXETINE; MIRTAZAPINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ARTICLE; BIPOLAR DISORDER; CAUCASIAN; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DYSTHYMIA; FKBP5 GENE; GENE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HAMILTON SCALE; HUMAN; MAJOR DEPRESSION; META ANALYSIS; MOOD DISORDER; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADULT; FEMALE; GENETIC ASSOCIATION STUDIES; GENOTYPE; HUMANS; LINEAR MODELS; MALE; MOOD DISORDERS; POLYMORPHISM, SINGLE NUCLEOTIDE; TACROLIMUS BINDING PROTEINS; TREATMENT OUTCOME;

EID: 78650621274     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2010.08.019     Document Type: Article

References (39)

1. Avissar S., Schreiber G. Toward molecular diagnostics of mood disorders in psychiatry. Trends Mol. Med. 2002, 8:294-300.
2. Baron M. Manic-depression genes and the new millennium: poised for discovery. Mol. Psychiatry 2002, 7:342-358.
3. Binder E.B. The role of FKBP5, a co-chaperone of the glucocorticoid receptor in the pathogenesis and therapy of affective and anxiety disorders. Psychoneuroendocrinology 2009, 34:S186-195.
4. Binder E.B., Salyakina D., Lichtner P., Wochnik G.M., Ising M., Pütz B., Papiol S., Seaman S., Lucae S., Kohli M.A., Nickel T., Künzel H.E., Fuchs B., Majer M., Pfennig A., Kern N., Brunner J., Modell S., Baghai T., Deiml T., Zill P., Bondy B., Rupprecht R., Messer T., Köhnlein O., Dabitz H., Brückl T., Müller N., Pfister H., Lieb R., Mueller J.C., Lõhmussaar E., Strom T.M., Bettecken T., Meitinger T., Uhr M., Rein T., Holsboer F., Muller-Myhsok B. Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat. Genet. 2004, 36:1319-1325.
5. Binder E.B., Lucae S., Salyakina D., Lichtner P., Meitinger T., Bondy B., Wochnik G., Rein T., Holsboer F., Müller-Myhsok B. SNPs in FKBP5 determine a novel subtype of depression characterized by rapid response to antidepressant treatment. Eur. Neuropsychopharmacol. 2006, 16:S75.
6. Brent D., Melhem N., Ferrell R., Emslie G., Wagner K.D., Ryan N., Vitiello B., Birmaher B., Mayes T., Zelazny J., Onorato M., Devlin B., Clarke G., DeBar L., Keller M. Association of FKBP5 polymorphisms with suicidal events in the Treatment of Resistant Depression in Adolescents (TORDIA) study. Am. J. Psychiatry 2010, 167:190-197.
7. Cheng R., Juo S.H., Loth J.E., Nee J., Iossifov I., Blumenthal R., Sharpe L., Kanyas K., Lerer B., Lilliston B., Smith M., Trautman K., Gilliam T.C., Endicott J., Baron M. Genome-wide linkage scan in a large bipolar disorder sample from the National Institute of Mental Health genetics initiative suggests putative loci for bipolar disorder, psychosis, suicide, and panic disorder. Mol. Psychiatry 2006, 11:252-260.
8. Cochran W.G. The combination of estimates from different experiments. Biometrics 1954, 10:101-129.
9. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin. Trials 1986, 7:177-188.
10. Egger M., Davey S.G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. Br. Med. J. 1997, 315:629-634.
11. Fava M. Management of nonresponse and intolerance: switching strategies. J. Clin. Psychiatry 2000, 61:10-12.
12. Fava M. Diagnosis and definition of treatment-resistant depression. Biol. Psychiatry 2003, 53:649-659.
13. Fava M., Davidson K.G. Definition and epidemiology of treatment-resistant depression. Psychiatr. Clin. North Am. 1996, 19:179-200.
14. Franchini L., Serretti A., Gasperini M., Smeraldi E. Familial concordance of fluvoxamine response as a tool for differentiating mood disorder pedigrees. J. Psychiatr. Res. 1998, 32:255-259.
15. Gawlik M., Moller-Ehrlich K., Mende M., Jovnerovski M., Jung S., Jabs B., Knapp M., Stoeber G. Is FKBP5 a genetic marker of affective psychosis? A case-control study and analysis of disease related traits. BMC Psychiatry 2006, 6:52.
16. Greenberg P.E., Stiglin L.E., Finkelstein S.N., Berndt E.R. The economic burden of depression in 1990. J. Clin. Psychiatry 1993, 54:405-418.
17. Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 1960, 23:56-62.
18. Higgins J.P., Thompson S.G. Quantifying heterogeneity in a meta-analysis. Stat. Med. 2002, 21:1539-1558.
19. Holsboer F. The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety. J. Psychiatr. Res. 1999, 33:181-214.
20. Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 2000, 23:477-501.
21. Holsboer F., Barden N. Antidepressants and hypothalamic-pituitary-adrenocortical regulation. Endocr. Rev. 1996, 17:187-205.
22. Horstmann S., Lucae S., Menke A., Hennings J.M., Ising M., Roeske D., Müller-Myhsok B., Holsboer F., Binder E.B. Polymorphisms in GRIK4, HTR2A, and FKBP5 show interactive effects in predicting remission to antidepressant treatment. Neuropsychopharmacology 2010, 35:727-740.
23. Kirchheiner J., Lorch R., Lebedeva E., Seeringer A., Roots I., Sasse J., Brockmöller J. Genetic variants in FKBP5 affecting response to antidepressant drug treatment. Pharmacogenomics 2008, 9:841-846.
24. Lavebratt C., Aberg E., Sjöholm L.K., Forsell Y. Variations in FKBP5 and BDNF genes are suggestively associated with depression in a Swedish population-based cohort. J. Affect. Disord. 2010.
25. Lekman M., Laje G., Charney D., Rush A.J., Wilson A.F., Sorant A.J., Lipsky R., Wisniewski S.R., Manji H., McMahon F.J., Paddock S. The FKBP5-gene in depression and treatment response-an association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Cohort. Biol. Psychiatry 2008, 63:1103-1110.
26. Mantel N., Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J. Natl. Cancer Inst. 1959, 22:719-748.
27. Munafo M.R., Flint J. Meta-analysis of genetic association studies. Trends Genet. 2004, 20:439-444.
28. Papiol S., Arias B., Gastó C., Gutiérrez B., Catalán R., Fañanás L. Genetic variability at HPA axis in major depression and clinical response to antidepressant treatment. J. Affect. Disord. 2007, 104:83-90.
29. Pare C.M., Rees L., Sainsbury M.J. Differentiation of two genetically specific types of depression by the response to anti-depressants. Lancet 1962, 2:1340-1343.
30. Pariante C.M., Miller A.H. Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol. Psychiatry 2001, 49:391-404.
31. Pratt W.B., Toft D.O. Steroid receptor interactions with heat shock protein and immunophilin chaperones. Endocr. Rev. 1997, 18:306-360.
32. Rush A.J., Bernstein I.H., Trivedi M.H., Carmody T.J., Wisniewski S., Mundt J.C., Shores-Wilson K., Biggs M.M., Woo A., Nierenberg A.A., Fava M. An evaluation of the quick inventory of depressive symptomatology and the Hamilton rating scale for depression: a sequenced treatment alternatives to relieve depression trial report. Biol. Psychiatry 2006, 59:493-501.
33. Sarginson J.E., Lazzeroni L.C., Ryan H.S., Schatzberg A.F., Murphy G.M. FKBP5 polymorphisms and antidepressant response in geriatric depression. Am. J. Med. Genet. B: Neuropsychiatr. Genet. 2010, 153B:554-560.
34. Sartorius N. The economic and social burden of depression. J. Clin. Psychiatry 2001, 62:8-11.
35. Sederer L.I., Thorbeck J. First do no harm: short-term inpatient psychotherapy of the borderline patient. Hosp. Community Psychiatry 1986, 37:692-697.
36. Tsai S.J., Hong C.J., Chen T.J., Yu Y.W. Lack of supporting evidence for a genetic association of the FKBP5 polymorphism and response to antidepressant treatment. Am. J. Med. Genet. B: Neuropsychiatr. Genet. 2007, 144B:1097-1098.
37. Willour V.L., Chen H., Toolan J., Belmonte P., Cutler D.J., Goes F.S., Zandi P.P., Lee R.S., MacKinnon D.F., Mondimore F.M., Schweizer B., DePaulo J.R., Gershon E.S., McMahon F.J., Potash J.B. Family-based association of FKBP5 in bipolar disorder. Mol. Psychiatry 2009, 14:261-268. Bipolar Disorder Phenome Group, NIMH Genetics Initiative Bipolar Disorder Consortium.
38. Wittchen H.U., Jacobi F. Size and burden of mental disorders in Europe-a critical review and appraisal of 27 studies. Eur. Neuropsychopharmacol. 2005, 15:357-376.
39. Zobel A., Schuhmacher A., Jessen F., Höfels S., von Widdern O., Metten M., Pfeiffer U., Hanses C., Becker T., Rietschel M., Scheef L., Block W., Schild H.H., Maier W., Schwab S.G. DNA sequence variants of the FKBP5 gene are associated with unipolar depression. Int. J. Neuropsychopharmacol. 2010, 1-12.